PMA
P230035: AGENT Paclitaxel-Coated Balloon Catheter
FDA PMA · Drug-eluting percutaneous transluminal coronary angioplasty catheter · Boston Scientific Corporation
Key facts
| PMA number | P230035 |
|---|---|
| Trade name | AGENT Paclitaxel-Coated Balloon Catheter |
| Generic name | Drug-eluting percutaneous transluminal coronary angioplasty catheter |
| Applicant | Boston Scientific Corporation |
| Owner/operator | Boston Scientific Corporation |
| Product code | OOB |
| Approval date | Feb 29, 2024 |
| Docket number | 24M-1081 |
| Notice date | Mar 8, 2024 |
| Establishment registration | 2124215 |
| FEI number | 2124215 |
At a glance
- 1–9 Supplements
- Aug 28, 2026 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- 10–99 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: